Quantcast

Industry news that matters to you.  Learn more

Archives for November 2010

U of T Researchers Unlock Clues to Thyroid Cancer

Researchers at the University of Toronto and Mount Sinai Hospital have utilized proteomic technologies to discover proteins secreted by thyroid cancer cell lines to identify and characterize potential biomarkers for the future management of thyroid carcinomas.

Instant Diagnoses via Lab-on-a-chip

Today, a blood sample whose protein content, genes and so on are to be read needs to be submitted to a series of complex processes, such as centrifugation, heat treatment, mixing with enzymes and concentration of disease markers. This means that samples are sent to central laboratories for analysis, and weeks may pass before the results are returned.

Little Benefit from Genomic Testing in CVD Prediction

An expert US group has concluded there is insufficient evidence to support genomic profiling for cardiovascular disease (CVD) risk prediction.

Pacific Biomarkers Poised to Join Battle Against Sharp Rise in Diabetes Cases Projected for the Year 2050 by Centers for Disease Control

Pacific Biomarkers, Inc., a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has responded to a recent report from the Centers for Disease Control projecting that as many as one in three adult Americans may suffer diabetes symptoms by the year 2050.

VeriStrat Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands. The intention of the biomarker analysis was to evaluate the ability of the blood-based test, VeriStrat, to predict patient outcomes with the erlotinib plus sorafenib combination regimen.